Article
In vitro development of imipenem/relebactam resistance in KPC-producing Klebsiella pneumoniae involves multiple mutations including OmpK36 disruption and KPC modification.
International journal of antimicrobial agents - 1 Oct 2023
Gato Eva, Guijarro-Sánchez Paula, Alonso-García Isaac, Pedraza-Merino Rosa, Conde Adrian, Lence Emilio, Rumbo-Feal Soraya, Peña-Escolano Andrea, Lasarte-Monterrubio Cristina, Blanco-Martín Tania, Fernández-González Ana, Fernández-López M Del Carmen, Maceiras Romina, Martínez-Guitián Marta, Vázquez-Ucha Juan Carlos, Martínez-Martínez Luis, González-Bello Concepción, Arca-Suárez Jorge, Beceiro Alejandro, Bou Germán
Abstract excerpt
OBJECTIVES: In order to inform and anticipate potential strategies aimed at combating KPC-producing Klebsiella pneumoniae infections, we analysed imipenem/relebactam and ceftazidime/avibactam single-step mutant frequencies, resistance development trajectories, differentially selected resistance mechanisms and their associated fitness cost using four representative high-risk K. pneumoniae clones. METHODS: Mutant...
Topics
Join the communities discussing this publication.